50 results about "Cyclosporins" patented technology

A method of preparing patients for cataract surgery includes topical administration of a cyclosporine solution. The administration may occur twice daily and may occur over the course of 28 days. The method results in an improved error prediction for 1-month spherical equivalent refractive outcome and improved ocular surface irregularity.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The application discloses a liposome drug carrier with mucosal adhesion, a preparation method and application thereof, and specifically, the drug carrier is DSPE-PEG-PBA, which can be used for loading cyclosporine A and crocin I, and the carrier of the application is used for loading cyclosporine A and crocin I. The liposome loaded with the two drugs has good stability and adhesion, can inhibit the side effect of cyclosporine A on the increase of ROS level, and has a wide application prospect in the treatment of inflammation and epithelial tissue damage.

The invention discloses a cyclosporin A combined self-assembly paclitaxel nano-drug and a preparation method and application thereof, and belongs to the field of biological medicine, the cyclosporin A combined self-assembly paclitaxel nano-drug is a nano-particle which is composed of paclitaxel, cyclosporin A and zinc ions and has a regular rod-like morphology, and the particle size of the nano-particle is 1-10 micrometers. The self-assembled paclitaxel nano-drug is prepared by combining cyclosporin A on the basis of a zinc ion coordinated supramolecular self-assembly strategy, so that the stability of the nano-drug can be improved, the toxic and side effects are reduced, the killing effect on drug-resistant tumors is enhanced, the approximate biological safety is retained, and the drug-resistant tumors are prevented from being damaged. The invention provides a new thought for overcoming the current situation of drug resistance of paclitaxel, and has important research value and wide application prospect.

Fungi are prolific producers of secondary metabolites and represent a rich and relatively untapped source for novel drug leads. Numerous successful therapeutics have derived from fungi, including penicillin, cephalosporin, statins, and cyclosporin. However, many promising classes of natural product are never developed into drugs because their chemical synthesis is complex or because the native organisms that naturally produce them, do so at impractically low levels. Pyridoxatins are a class of promising anti-fungal secondary metabolites produced by several naturally occurring strains filamentous fungi. The molecules have complex structures that impede straightforward chemical synthesis or analoging to increase efficacy. The disclosure herein details novel a novel use of pyridoxatin class molecules for the treatment of Candida auris and novel methods for the biosynthesis of pyridoxatins through fermentation of engineered microbes.

The application belongs to the technical field of microorganisms, and particularly relates to a Fusarium solani strain for fermenting cyclosporin A, and further discloses application of the Fusarium solani strain for fermenting cyclosporin A. The application screens a Fusarium solani FIM-CS-66-69 strain for high-yield cyclosporin A by using an atmospheric pressure room temperature plasma mutagenesis technology, the Fusarium solani FIM-CS-66-69 strain can ferment cyclosporin A at a high yield, in a fermentation experiment, the Fusarium solani FIM-CS-66-69 strain can ferment cyclosporin A at a titer of 16551 ug / mL, the yield of cyclosporin A is greatly improved, and the content of homologues is low, so that the Fusarium solani FIM-CS-66-69 strain is more suitable for industrialized fermentation production.

The invention relates to a recovery method of cyclosporin A crystallization mother liquor, which comprises the following steps: carrying out previous treatment and impurity removal on the cyclosporin A crystallization mother liquor, carrying out primary crystallization with a polar solvent, carrying out secondary crystallization with a non-polar solvent, and finally carrying out crystal transformation and drying with the polar solvent to obtain a cyclosporin A finished product. According to the method, the residual cyclosporin A in the crystallization mother liquor is effectively purified, waste of the residual cyclosporin A in the crystallization mother liquor is avoided, the production cost of the cyclosporin A can be remarkably reduced, the method is suitable for industrial production, the product content reaches 98.5% or above, and the maximum single impurity content is within 0.7%.

This invention relates to the field of insect control, specifically to the Paecilomyces lilacinus strain XI-5, and the extraction and identification of crude toxins produced by secondary metabolites of Paecilomyces lilacinus strain XI-5. This invention confirms that the secondary metabolites of Paecilomyces lilacinus strain XI-5 produce cyclosporine C. Cyclosporine C has a stomach poison effect on adult whiteflies. Twenty-four hours after application, the LC50 concentration of cyclosporine C against adult whiteflies was 31.75 µg / ml; compared to the control group, the LC30 concentration of cyclosporine C resulted in a decrease in oviposition / fertility in female whiteflies.

The present invention relates to the field of pharmaceutical technology and relates to emulsion compositions comprising the active pharmaceutical ingredient Cyclosporin and the method of preparing this composition.

Provided is a medicine and a method for inhibiting over-activated immunity before pregnancy or over-reactive immunity after pregnancy and restoring normal immune state. A medicine for inhibiting over-activated immunity before pregnancy or over-reactive immunity after pregnancy and restoring a normal immune state, includes, as an active ingredient, a compound selected from the group consisting of: (i) a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:wherein the respective reference numerals are as described in the specification, (ii) a cyclosporine, and (iii) rapamycin or a derivative thereof.

The application discloses application of pulegone as an effective component in an immunosuppressant, and the pulegone with significant calcineurin (CN) inhibiting activity is screened from the Schleichera oleosa Kurz, the immunosuppressive effect of the pulegone is equivalent to that of cyclosporine A which is widely used in clinic, mechanism research shows that the pulegone targets CN / NFAT signal path to play the immunosuppressive activity, and the pulegone has very weak cytotoxicity to spleen cells, and is a high-efficiency and low-toxicity immunosuppressant.

The present disclosure provides a suspension-type eye drop having excellent redispersibility. More specifically, the present disclosure provides an aqueous-based suspension formulation containing a first component and a second component wherein the first component is (E)-2-(7-trifluoromethylchroman-4-subunit)-N-(7-hydroxy-5, 6, 7, 8-tetrahydronaphthalene-1-yl) acetamide, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable salt or solvate thereof. And the second component comprises at least one component selected from the group consisting of diquafosol, cyclosporin, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof.

Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

The present invention provides a pharmaceutical composition which contains a population of cells, wherein the cells comprise cells that accumulate in an inflamed site and particles that are introduced into the cells and contain a bioabsorbable polymer and a drug, and the drug is cyclosporin or minoxidil.

This article discloses cyclosporine compounds and methods for treating or preventing neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.

The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPRL.

Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.

The present invention relates to a nanoemulsion ophthalmic composition and a preparation method thereof, wherein the nanoemulsion ophthalmic composition is obtained by mixing cyclosporine, castor oil, hydrophilic and hydrophobic emulsifiers, menthol, and an aqueous solvent, and thus exhibits excellent stability as well as ameliorating ocular irritation such as a feeling of grittiness, blurry vision, and the like.

The present invention discloses a preparation method and application of a biomimetic brain-targeted cyclosporine A (CsA) nanoparticle crystal drug. The composition of the biomimetic brain-targeted CsA nanocrystal drug is CsA and platelet membrane (M- PLT ), and M- PLT is wrapped on the surface of CsA nanocrystals by the polycarbonate membrane extrusion method (CsA@M- PLT ), improving the stability of CsA nanocrystals and the targeting property to the brain injury site. The drug loading of CsA in CsA@M- PLT is 49.17%. After being taken up by neurons, CsA@M- PLT can restore the mitochondrial membrane potential of neurons, reduce the release of mitochondrial ROS, and inhibit the apoptosis of neuron cells; CsA@M- PLT can reduce the damage of the blood-brain barrier, reduce brain edema, and treat secondary brain injury efficiently through multiple pathways.

The present disclosure provides methods of inhibiting amyloid synthesis in a subject using small molecule inhibitors. The invention also includes methods of treating disease associated with amyloid synthesis, such as Alzheimer's disease. The small molecule inhibitors disclosed herein are compounds which are non-immunosuppressant cyclosporin including the pharmaceutically acceptable salts thereof.

The application discloses a cyclosporine A solid self-emulsifying drug composition and a preparation method thereof, and the drug composition comprises, in percentage by mass, 60-75% of a carrier material, 16.7-33.3% of a compatibility adjusting material, and the rest of cyclosporine A, and the sum of the mass percentages of all raw materials is 100%. The application is innovative in process from two aspects of selection of a compatibility adjusting material and a drug loading mode by developing a brand-new pre-molecularization-co-extrusion mode, and a ternary amorphous solid dispersion of cyclosporine A with strong compatibility and high stability is designed. The application fully utilizes the dissolution advantage of the amorphous solid dispersion technology, promotes the release of cyclosporine A, and simultaneously, due to the formation of a self-assembled sub-micro emulsion system, the intestinal permeability of cyclosporine A is significantly improved, and therefore, the application is a new preparation strategy which is safe and effective, green and environmentally-friendly, and has application prospects.

Provided herein are combinations comprising: 1) acoltremon; and 2) lifitegrast or cyclosporin, or a pharmaceutically acceptable salt thereof. The combinations are useful for treating dry eye or dysfunctional tear syndrome, or a sign or symptom thereof.

The present application relates to the field of nanoemulsions, in particular, cannabinoid-comprising nanoemulsions. The present disclosure provides cannabinoid (e.g., THC, CBD, CBDi or combinations of THC and CBD) comprising nanoemulsions that may optionally further comprise cyclosporine as methods of using the disclosed nanoemulsions to treat ophthalmic conditions such as dry eye. The disclosed formulations have significantly improved pharmaceutical stability in a variety of tested conditions when compared to conventional formulations.